Sandra Horning, MD
The FDA has granted a priority review to a supplemental new drug application (sNDA) for alectinib (Alecensa) for the frontline treatment of patients with ALK
-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.
FDA grants Genentech’s Alecensa priority review for initial treatment of people with ALK-positive lung cancer. Genentech. Available at: http://bit.ly/2u67edG. Accessed August 3, 2017.
... to read the full story